<DOC>
	<DOCNO>NCT01117818</DOCNO>
	<brief_summary>This multiple vaccination study find safe treatment effect symptoms early Alzheimer 's disease male female patient age 50 80 year . Approximately 40 study site Europe involve . Patients randomize receive either AFFITOPE AD02 placebo . Each patient 's participation last 1 year .</brief_summary>
	<brief_title>Clinical- Immunological Activity , Safety Tolerability Different Doses / Formulations AFFITOPE AD02 Early Alzheimer 's Disease</brief_title>
	<detailed_description>AFFITOPE AD02 second generation AD immunotherapeutics target Aβ . Its active component synthetic peptide functionally mimic unmodified N-terminus Aβ .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Informed consent capability Early AD , base episodic memory deficit hippocampal atrophy Age 50 80 , inclusive MMSE 20+ Brain magnetic resonance image scan consistent diagnosis AD Stable dose medication ( cholinesterase inhibitor memantine allow ) Caregiver able attend visit patient Significant neurological disease AD Major psychiatric illness Significant systemic illness Autoimmune disease Prior treatment experimental immunotherapeutics AD include IVIG Women childbearing potential without birth control Contraindication MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>